Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$4.87 -3.2%	$5.29	$4.71 ▼ $12.43	$704.30M	1.36	2.15 million shs	1.53 million shs
DRNA Dicerna Pharmaceuticals	$38.22	$38.12	$19.06 ▼ $40.14	$2.99B	0.8	1.34 million shs	N/A
KRON Kronos Bio	$0.98 +2.1%	$1.14	$0.73 ▼ $2.29	$58.90M	1.82	308,907 shs	757,128 shs
MDGL Madrigal Pharmaceuticals	$194.38 -5.0%	$244.08	$119.76 ▼ $322.67	$3.87B	-0.47	530,472 shs	707,187 shs
YMAB Y-mAbs Therapeutics	$14.84 -2.9%	$15.79	$4.60 ▼ $20.90	$649.65M	0.74	401,791 shs	365,385 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-1.18%	+2.44%	+0.80%	-37.44%	-54.56%
DRNA Dicerna Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KRON Kronos Bio	+1.05%	-7.69%	-21.95%	-17.24%	-27.82%
MDGL Madrigal Pharmaceuticals	-6.29%	-10.37%	-17.35%	-11.09%	-30.81%
YMAB Y-mAbs Therapeutics	-0.33%	+1.19%	-2.67%	+45.07%	+164.53%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	1.2581 of 5 stars	3.4	3.0	0.0	0.0	1.1	0.0	0.6
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	3.3064 of 5 stars	3.5	4.0	0.0	0.0	0.6	4.2	1.3
MDGL Madrigal Pharmaceuticals	4.7093 of 5 stars	4.4	1.0	0.0	4.6	3.1	4.2	0.6
YMAB Y-mAbs Therapeutics	1.0353 of 5 stars	2.2	1.0	0.0	0.0	1.7	4.2	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.75	Moderate Buy	$10.00	105.34% Upside
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A
KRON Kronos Bio	3.00	Buy	$4.25	333.67% Upside
MDGL Madrigal Pharmaceuticals	2.73	Moderate Buy	$356.73	83.52% Upside
YMAB Y-mAbs Therapeutics	2.33	Hold	$16.57	11.67% Upside

Current Analyst Ratings

Latest DRNA, KRON, YMAB, AUPH, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	MDGL Madrigal Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$150.00
3/20/2024	MDGL Madrigal Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$325.00 ➝ $405.00
3/15/2024	MDGL Madrigal Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$405.00 ➝ $425.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $377.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$320.00 ➝ $375.00
3/15/2024	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$351.00 ➝ $397.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$382.00 ➝ $389.00
3/15/2024	MDGL Madrigal Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $390.00
3/15/2024	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$337.00 ➝ $410.00
3/15/2024	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$155.00 ➝ $270.00
3/6/2024	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$175.51M	4.01	N/A	N/A	$2.63 per share	1.85
DRNA Dicerna Pharmaceuticals	$164.31M	18.17	N/A	N/A	$1.84 per share	20.77
KRON Kronos Bio	$6.29M	9.36	N/A	N/A	$2.73 per share	0.36
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	$20.53 per share	N/A
YMAB Y-mAbs Therapeutics	$84.82M	7.66	N/A	N/A	$2.32 per share	6.40

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	-$0.54	N/A	8.85	N/A	-44.45%	-20.10%	-14.84%	5/2/2024 (Confirmed)
DRNA Dicerna Pharmaceuticals	-$112.75M	-$1.63	N/A	N/A	N/A	-64.53%	-103.08%	-16.58%	N/A
KRON Kronos Bio	-$112.67M	-$1.95	N/A	N/A	N/A	-1,791.87%	-58.79%	-45.03%	5/8/2024 (Estimated)
MDGL Madrigal Pharmaceuticals	-$373.63M	-$19.94	N/A	N/A	N/A	N/A	-219.39%	-98.75%	5/7/2024 (Confirmed)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.49	N/A	N/A	N/A	-25.26%	-20.72%	-16.28%	5/13/2024 (Estimated)

Latest DRNA, KRON, YMAB, AUPH, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2024	N/A	MDGL Madrigal Pharmaceuticals	-$6.06	N/A	+$6.06	N/A	N/A	N/A
5/2/2024	N/A	AUPH Aurinia Pharmaceuticals	-$0.17	N/A	+$0.17	N/A	N/A	N/A
3/21/2024	Q4 2023	KRON Kronos Bio	-$0.51	-$0.43	+$0.08	-$0.43	$1.50 million	$2.29 million
2/29/2024	Q4 2023	YMAB Y-mAbs Therapeutics	-$0.19	-$0.02	+$0.17	-$0.02	$21.72 million	$23.36 million
2/28/2024	Q4 2023	MDGL Madrigal Pharmaceuticals	-$5.26	-$5.68	-$0.42	-$5.68	N/A	N/A
2/15/2024	12/31/2023	AUPH Aurinia Pharmaceuticals	-$0.16	-$0.19	-$0.03	-$0.19	$45.00 million	$45.10 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.20	5.50	4.99
DRNA Dicerna Pharmaceuticals	N/A	2.46	2.46
KRON Kronos Bio	N/A	7.24	7.24
MDGL Madrigal Pharmaceuticals	0.28	5.38	5.38
YMAB Y-mAbs Therapeutics	N/A	5.52	5.27

Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
DRNA Dicerna Pharmaceuticals	78.91%
KRON Kronos Bio	64.09%
MDGL Madrigal Pharmaceuticals	98.50%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	4.30%
DRNA Dicerna Pharmaceuticals	10.20%
KRON Kronos Bio	23.40%
MDGL Madrigal Pharmaceuticals	23.92%
YMAB Y-mAbs Therapeutics	21.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	144.62 million	138.40 million	Optionable
DRNA Dicerna Pharmaceuticals	302	78.13 million	70.16 million	Optionable
KRON Kronos Bio	62	60.10 million	46.03 million	Optionable
MDGL Madrigal Pharmaceuticals	376	19.90 million	15.14 million	Optionable
YMAB Y-mAbs Therapeutics	100	43.78 million	34.37 million	Optionable

DRNA, KRON, YMAB, AUPH, and MDGL Headlines

Source	Headline
	Y-mAbs to Present at 2024 ASCO Annual Meeting globenewswire.com - April 25 at 4:05 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7% marketbeat.com - April 23 at 4:47 PM
	New Strong Buy Stocks for April 19th zacks.com - April 19 at 7:50 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161% finance.yahoo.com - April 18 at 1:21 PM
	New Strong Buy Stocks for April 17th zacks.com - April 17 at 8:30 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4% marketbeat.com - April 11 at 11:58 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analysts marketbeat.com - April 10 at 2:30 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% marketbeat.com - April 9 at 11:46 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2% marketbeat.com - April 3 at 3:27 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19 marketbeat.com - April 2 at 11:19 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9% marketbeat.com - April 1 at 2:01 PM
	Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - April 1 at 6:12 AM
	Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet zacks.com - March 28 at 10:56 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9% marketbeat.com - March 26 at 12:38 PM
	YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? zacks.com - March 20 at 8:40 AM
	Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns marketwatch.com - March 15 at 8:31 AM
	Y-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer finanznachrichten.de - March 14 at 2:58 PM
	Y-mAbs Therapeutics CFO Bo Kruse To Retire markets.businessinsider.com - March 14 at 9:57 AM
	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer globenewswire.com - March 14 at 9:05 AM
	Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High? zacks.com - March 12 at 10:55 AM
	BAMF, Corewell Health partner on clinical trial for advanced cancer treatment crainsgrandrapids.com - March 11 at 3:17 PM
	Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics markets.businessinsider.com - March 6 at 6:21 PM
	Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice zacks.com - March 5 at 1:01 PM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 4 at 1:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aurinia Pharmaceuticals

NASDAQ:AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Dicerna Pharmaceuticals

NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Kronos Bio

NASDAQ:KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

Madrigal Pharmaceuticals

NASDAQ:MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Y-mAbs Therapeutics

NASDAQ:YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial